Bangzhi Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bangzhi Zhang has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
Jianfeng Zhang
Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences & Research Unit of Peptide Science, Chinese Academy of Medical Science, Lanzhou University, Lanzhou 730000, China
9 shared publicationsRunling Yang
Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences & Research Unit of Peptide Science, Chinese Academy of Medical Science, 2019RU066, Lanzhou University, Lanzhou 730000, China
7 shared publicationsXiaocui Feng
Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences & Research Unit of Peptide Science, Chinese Academy of Medical Science, 2019RU066, Lanzhou University, Lanzhou 730000, China
7 shared publicationsJingya Bai
Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences & Research Unit of Peptide Science, Chinese Academy of Medical Science, Lanzhou University, Lanzhou 730000, China
6 shared publicationsBochuan Deng
Lanzhou University, China
5 shared publications- Junqiu Xie
Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences & Research Unit of Peptide Science, Chinese Academy of Medical Sciences, 2019RU066
5 shared publications
Latest Publications
- 16 March 2026
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 137, 118630
Optimization of CaMKII inhibitory peptide with N-terminal fatty acid chain modification and its study on anti-kidney fibrosis
- 16 March 2026
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 137, 118630
Optimization of CaMKII inhibitory peptide with N-terminal fatty acid chain modification and its study on anti-kidney fibrosis
- 14 February 2026
- Published by Elsevier in Experimental Cell Research
- Vol. 457 (2) , 114939
miR-30e-5p in renal fibrosis: Cross-species multi-model profiling of dynamic networks and clinical prospects
- 14 February 2026
- Published by Elsevier in Experimental Cell Research
- Vol. 457 (2) , 114939
miR-30e-5p in renal fibrosis: Cross-species multi-model profiling of dynamic networks and clinical prospects
- Top Cited Papers
- 20 January 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1015, 178567
Peptide FK2 attenuates inflammation and pro-fibrotic cellular transitions via targeting the IKKβ/NF-κB/TGF-β1 axis in renal fibrosis
- 20 January 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1015, 178567
Top Cited PapersPeptide FK2 attenuates inflammation and pro-fibrotic cellular transitions via targeting the IKKβ/NF-κB/TGF-β1 axis in renal fibrosis
- Open Access
- 11 August 2025
- Published by Springer Nature in Discover Medicine
- Vol. 2 (1) , 1-23
Whole-transcriptome sequencing reveals key biomarkers and pathways in renal fibrosis
To systematically delineate the transcriptomic landscape of progressive renal fibrosis and identify its critical biomarkers using a systems biology approach, we performed whole-transcriptome sequencing employing a mouse model with fibrotic kidneys caused by Unilateral Ureteral Obstruction (UUO) at three distinct time points (After 3, 7, and 14 days of UUO). Subsequently, gene set enrichment analysis (GSEA) and differential expression analysis was independently carried out on the UUO and sham groups, this was followed by an analysis predicting functional interactions to form a network of competing endogenous RNA (ceRNA) complexes for the purpose of identifying significant biomarkers. Moreover, multiple Gene Expression Omnibus (GEO) datasets along with sequential quantitative real-time PCR (qPCR) experiments were carried out to validate the results. Overall, 876 messenger RNAs with differential expression (dif-mRNAs), 53 microRNAs with differential expression (dif-miRNAs) and 296 long non-coding RNAs with differential expression (dif-lncRNAs) sustained differential expression throughout the emergence and advancement of renal fibrosis. Enrichment analysis on all detected genes, dif-mRNAs, PPI network module genes, and hub genes, along with those genes individually related to dif-miRNA and dif-lncRNA, all identified functions pertained to the cell cycle. A large number of dif-mRNAs and dif-miRNAs have been successfully validated by GEO data. Notably, Kif20a, Cep55, Mki67, Morrbid, and Dnm3os are upregulated and significantly enriched nodes in the ceRNA network. Particularly, miR-30e-5p is downregulated, prominently featured in the ceRNA network, and selectively expressed in the kidney. This downregulation is also reflected in plasma and urine, aligning with the renal tissue findings. In summary, Kif20a, Cep55, Mki67, Morrbid, and Dnm3os, along with miR-30e-5p, may be pivotal in driving progressive renal fibrosis and have strong potential as clinical biomarkers.
- 11 August 2025
- Published by Springer Nature in Discover Medicine
- Vol. 2 (1) , 1-23
Open AccessWhole-transcriptome sequencing reveals key biomarkers and pathways in renal fibrosis
To systematically delineate the transcriptomic landscape of progressive renal fibrosis and identify its critical biomarkers using a systems biology approach, we performed whole-transcriptome sequencing employing a mouse model with fibrotic kidneys caused by Unilateral Ureteral Obstruction (UUO) at three distinct time points (After 3, 7, and 14 days of UUO). Subsequently, gene set enrichment analysis (GSEA) and differential expression analysis was independently carried out on the UUO and sham groups, this was followed by an analysis predicting functional interactions to form a network of competing endogenous RNA (ceRNA) complexes for the purpose of identifying significant biomarkers. Moreover, multiple Gene Expression Omnibus (GEO) datasets along with sequential quantitative real-time PCR (qPCR) experiments were carried out to validate the results. Overall, 876 messenger RNAs with differential expression (dif-mRNAs), 53 microRNAs with differential expression (dif-miRNAs) and 296 long non-coding RNAs with differential expression (dif-lncRNAs) sustained differential expression throughout the emergence and advancement of renal fibrosis. Enrichment analysis on all detected genes, dif-mRNAs, PPI network module genes, and hub genes, along with those genes individually related to dif-miRNA and dif-lncRNA, all identified functions pertained to the cell cycle. A large number of dif-mRNAs and dif-miRNAs have been successfully validated by GEO data. Notably, Kif20a, Cep55, Mki67, Morrbid, and Dnm3os are upregulated and significantly enriched nodes in the ceRNA network. Particularly, miR-30e-5p is downregulated, prominently featured in the ceRNA network, and selectively expressed in the kidney. This downregulation is also reflected in plasma and urine, aligning with the renal tissue findings. In summary, Kif20a, Cep55, Mki67, Morrbid, and Dnm3os, along with miR-30e-5p, may be pivotal in driving progressive renal fibrosis and have strong potential as clinical biomarkers.
- 16 February 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 234, 116803
Parps in immune response: Potential targets for cancer immunotherapy
- 16 February 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 234, 116803
Parps in immune response: Potential targets for cancer immunotherapy
- 27 August 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 982, 176942
The novel peptide PEP-Z-2 potentially treats renal fibrosis in vivo and in vitro by regulating TGF-β/Smad/AKT/MAPK signaling
- 27 August 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 982, 176942
The novel peptide PEP-Z-2 potentially treats renal fibrosis in vivo and in vitro by regulating TGF-β/Smad/AKT/MAPK signaling
- 7 March 2024
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 389 (2) , 208-218
Beclin-1–Derived Peptide MP1 Attenuates Renal Fibrosis by Inhibiting the Wnt/β-Catenin Pathway
Renal fibrosis is distinguished by the abnormal deposition of extracellular matrix (ECM) and progressive loss of nephron function, with a lack of effective treatment options in clinical practice. In this study, we discovered that the Beclin-1-derived peptide MP1 significantly inhibits the abnormal expression of fibrosis and Epithelial-mesenchymal transition (EMT)-related markers, including α-Smooth muscle actin (α-SMA), Fibronectin (FN), Collagen I (Col I), Matrix metallopeptidase 2 (MMP2), Snail1, and Vimentin (Vim) both in vitro and in vivo. Hematoxylin-eosin (H&E) staining was employed to evaluate renal function, while serum creatinine (Scr) and blood urea nitrogen (BUN) were used as main indices to assess pathological changes in the obstructed kidney. The results demonstrated that daily treatment with MP1 during the 14-day experiment significantly alleviated renal dysfunction and changes in Scr and BUN in mice with unilateral ureteral obstruction (UUO). Mechanistic research revealed that MP1 was found to have a significant inhibitory effect on the expression of crucial components involved in both the Wnt/β-Catenin and TGF-β/Smad pathways, including β-Catenin, C-Myc, Cyclin D1, TGF-β1, and p-Smad/Smad. However, MP1 exhibited no significant impact on either the LC3II/LC3I ratio or P62 levels. These findings indicate that MP1 improves renal physiological function and mitigates the fibrosis progression by inhibiting the Wnt/β-Catenin pathway. Our study suggests that MP1 represents a promising and novel candidate drug precursor for the treatment of renal fibrosis. Significance Statement Our study indicated that the Beclin-1-derived peptide MP1 effectively mitigated renal fibrosis induced by UUO through inhibiting the Wnt/β-Catenin pathway and TGF-β/Smad pathway, thereby improving renal physiological function. Importantly, unlike other Beclin-1-derived peptides, MP1 exhibited no significant impact on autophagy in normal cells. MP1 represents a promising and novel candidate drug precursor for the treatment of renal fibrosis focusing on Beclin-1 derivatives and Wnt/β-Catenin pathway.
- 7 March 2024
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 389 (2) , 208-218
Beclin-1–Derived Peptide MP1 Attenuates Renal Fibrosis by Inhibiting the Wnt/β-Catenin Pathway
Renal fibrosis is distinguished by the abnormal deposition of extracellular matrix (ECM) and progressive loss of nephron function, with a lack of effective treatment options in clinical practice. In this study, we discovered that the Beclin-1-derived peptide MP1 significantly inhibits the abnormal expression of fibrosis and Epithelial-mesenchymal transition (EMT)-related markers, including α-Smooth muscle actin (α-SMA), Fibronectin (FN), Collagen I (Col I), Matrix metallopeptidase 2 (MMP2), Snail1, and Vimentin (Vim) both in vitro and in vivo. Hematoxylin-eosin (H&E) staining was employed to evaluate renal function, while serum creatinine (Scr) and blood urea nitrogen (BUN) were used as main indices to assess pathological changes in the obstructed kidney. The results demonstrated that daily treatment with MP1 during the 14-day experiment significantly alleviated renal dysfunction and changes in Scr and BUN in mice with unilateral ureteral obstruction (UUO). Mechanistic research revealed that MP1 was found to have a significant inhibitory effect on the expression of crucial components involved in both the Wnt/β-Catenin and TGF-β/Smad pathways, including β-Catenin, C-Myc, Cyclin D1, TGF-β1, and p-Smad/Smad. However, MP1 exhibited no significant impact on either the LC3II/LC3I ratio or P62 levels. These findings indicate that MP1 improves renal physiological function and mitigates the fibrosis progression by inhibiting the Wnt/β-Catenin pathway. Our study suggests that MP1 represents a promising and novel candidate drug precursor for the treatment of renal fibrosis. Significance Statement Our study indicated that the Beclin-1-derived peptide MP1 effectively mitigated renal fibrosis induced by UUO through inhibiting the Wnt/β-Catenin pathway and TGF-β/Smad pathway, thereby improving renal physiological function. Importantly, unlike other Beclin-1-derived peptides, MP1 exhibited no significant impact on autophagy in normal cells. MP1 represents a promising and novel candidate drug precursor for the treatment of renal fibrosis focusing on Beclin-1 derivatives and Wnt/β-Catenin pathway.
- Open Access
- 18 October 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Toward a General Glycosylation Strategy: Exploring the Dual Functions of Acyl Group Direction in Various Nucleophilic Environments
A universal glycosylation strategy could significantly simplify glycoside synthesis. One approach to achieving this goal is through acyl group stereodirecting participation for the corresponding 1,2-, 1,3-, 1,4-, or 1,6-trans glycosylation; how-ever, this approach had been challenging for glycosidic bonds that require distal equatorial-acyl group direction. We have developed an approach in weakly nucleophilic environments for selective 1,4-trans glycosylation directed by the equato-rial-4-O-acyl group. Here, we explored this condition in other distal acyl groups and found, besides stereodirecting partic-ipation, acyl groups also mediated hydrogen bonding between acyl groups and alcohols. The latter showed a diverse ef-fect and classified the acyl group direction into axial and equatorial categories. Corresponding glycosylation conditions were distinguished as guidance for acyl group direction from either category. Hence, the acyl group direction may serve as a general glycosylation strategy.
- 18 October 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessToward a General Glycosylation Strategy: Exploring the Dual Functions of Acyl Group Direction in Various Nucleophilic Environments
A universal glycosylation strategy could significantly simplify glycoside synthesis. One approach to achieving this goal is through acyl group stereodirecting participation for the corresponding 1,2-, 1,3-, 1,4-, or 1,6-trans glycosylation; how-ever, this approach had been challenging for glycosidic bonds that require distal equatorial-acyl group direction. We have developed an approach in weakly nucleophilic environments for selective 1,4-trans glycosylation directed by the equato-rial-4-O-acyl group. Here, we explored this condition in other distal acyl groups and found, besides stereodirecting partic-ipation, acyl groups also mediated hydrogen bonding between acyl groups and alcohols. The latter showed a diverse ef-fect and classified the acyl group direction into axial and equatorial categories. Corresponding glycosylation conditions were distinguished as guidance for acyl group direction from either category. Hence, the acyl group direction may serve as a general glycosylation strategy.
- Open Access
- 4 August 2023
- Published by American Chemical Society (ACS) in ChemRxiv
β-L-Rhamnosylation and β-D-Mannosylation Mediated by 4-O-Ester Groups in Weakly Nucleophilic Environment
Eq-4-O-acyl group directed β-rhamnosylation and β-mannosylation are achieved in carborane or BARF anion formed weakly nucleophilic environment with the assistance of a 2,3-orthocarbonate group. The 4-O-acyl group plays a critical role in directing the β-selectivity, and the weakly coordinating anion is essential to amplify this direction. The orthocarbonate group could be readily removed with 1,3-propanediol in the presence of BF3.Et2O.
- 4 August 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open Accessβ-L-Rhamnosylation and β-D-Mannosylation Mediated by 4-O-Ester Groups in Weakly Nucleophilic Environment
Eq-4-O-acyl group directed β-rhamnosylation and β-mannosylation are achieved in carborane or BARF anion formed weakly nucleophilic environment with the assistance of a 2,3-orthocarbonate group. The 4-O-acyl group plays a critical role in directing the β-selectivity, and the weakly coordinating anion is essential to amplify this direction. The orthocarbonate group could be readily removed with 1,3-propanediol in the presence of BF3.Et2O.